Multi-Stakeholder Call to Action for the Future of Vaccine Post-Marketing Monitoring: Proceedings from the First Beyond COVID-19 Monitoring Excellence (BeCOME) Conference

Vincent Bauchau, Kaatje Bollaerts, Phil Bryan, Jim Buttery, Kourtney Davis, Robert T. Chen, Daniel R. Feikin, Antonella Fretta, Sarah Frise (), Sonja Gandhi-Banga, Hector S. Izurieta, Corinne Jouquelet-Royer, Alena Khromava, Lin Li, Raj Long, Sarah MacDonald, Lydie Marcelon, Robert Massouh, Wilhelmine Meeraus, Flor M. Munoz, Karen Naim, Dale Nordenberg, Hanna Nohynek, Heather Rubino, Daniel A. Salmon, Sarah Sellers, Laurence Serradell, Laurence Torcel-Pagnon and Jamie Wilkins
Additional contact information
Vincent Bauchau: Independent, Previously GSK, Vaccine Safety
Kaatje Bollaerts: P95 (Epidemiology and Pharmacovigilance Consultant and Services)
Phil Bryan: GSK (Safety Evaluation and Risk Management)
Jim Buttery: Murdoch Childrens Research Institute, University of Melbourne
Kourtney Davis: Janssen Research and Development LLC (Global Epidemiology)
Robert T. Chen: Brighton Collaboration (A Program of the Task Force for Global Health)
Daniel R. Feikin: World Health Organization
Antonella Fretta: Pfizer (Worldwide Medical & Safety)
Sarah Frise: AstraZeneca (Global Patient Safety)
Sonja Gandhi-Banga: Sanofi (Global Pharmacovigilance)
Hector S. Izurieta: US Food and Drug Administration (Center for Biologics Evaluation and Research)
Corinne Jouquelet-Royer: Sanofi (Patient Safety and Pharmacovigilance)
Alena Khromava: Sanofi (Global Pharmacovigilance)
Lin Li: Sanofi (Epidemiology and Benefit Risk)
Raj Long: Independent, Previously Bill & Melinda Gates Foundation (Safety & Pharmacovigilance)
Sarah MacDonald: Pfizer (Worldwide Medical & Safety)
Lydie Marcelon: Sanofi (Epidemiology and Benefit Risk Evaluation)
Robert Massouh: GSK (Safety Evaluation and Risk Management)
Wilhelmine Meeraus: AstraZeneca (Medical Evidence, Vaccines & Immune Therapies)
Flor M. Munoz: Baylor College of Medicine and Texas Children’s Hospital
Karen Naim: Pfizer (Worldwide Medical & Safety)
Dale Nordenberg: Thriive.AI
Hanna Nohynek: National Institute for Health and Welfare (Infectious Diseases Control and Vaccines)
Heather Rubino: Pfizer (Worldwide Medical & Safety)
Daniel A. Salmon: Johns Hopkins Bloomberg
Sarah Sellers: Novavax (Safety Science and Surveillance)
Laurence Serradell: Sanofi (Epidemiology and Benefit Risk Evaluation)
Laurence Torcel-Pagnon: Sanofi (Vaccines Medical Global Evidence Generation Influenza)
Jamie Wilkins: Pfizer (Worldwide Medical & Safety)

Drug Safety, 2025, vol. 48, issue 5, No 9, 577-585

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-024-01510-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:48:y:2025:i:5:d:10.1007_s40264-024-01510-9

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-024-01510-9

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().